TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04432103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients
Description: Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 severe cases.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients
Description: Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 critical cases.
Study: NCT04126213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV MAT 60 µg
Description: One single dose of RSV MAT 60 µg vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV MAT 120 µg
Description: One single dose of RSV MAT 120 µg vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single dose of placebo (NaCl solution) administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
Study: NCT01371266

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Honey
Description: 60.7 grams orally daily times 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Honey
Description: 60.7 grams orally daily times 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Fructose Corn Syrup 55 (HFCS 55)
Description: 65.7 gram daily orally times 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Fructose Corn Syrup 55 (HFCS 55)
Description: 65.7 gram daily orally times 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CHO (sugar)
Description: 50 grams daily orally times 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CHO (sugar)
Description: 50 grams daily orally times 14 days
Study: NCT02987959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-228
Description: TAK-228 is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128) targets 2 distinct mTOR complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
Study: NCT01183221

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Syntocinon
Description: One dose of 24 IU (3 sprays/nostril)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon
Description: One dose of 24 IU (3 sprays/nostril)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intranasal Placebo
Study: NCT02674321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-809
Study: NCT02890030

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: * Neurotoxicity~* Medications of interest~* General health~* Family history
Study: NCT01294826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: Weekly intravenous infusion on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of AUY922 is 40, 55, and 70 mg/m2 will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered after each AUY922 infusion, intravenously on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression.
Study: NCT03582826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counselling
Description: Behavioral nutritional counselling delivered via the Internet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress-reduction counseling
Description: The psycho-behavioral intervention includes administering questionnaires and monthly maintenance psychological support delivered via the Internet.
Study: NCT04178070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB224 2mg
Description: 2mg (100μL), single dose, abdominal subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB224 5mg
Description: 5mg (250μL), single dose, abdominal subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB224 10mg
Description: 10mg (500μL), single dose, abdominal subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB224 15mg
Description: 15mg (750μL), single dose, abdominal subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB224 20mg
Description: 20mg (1mL), single dose, abdominal subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB224 30mg
Description: 30mg (1.5mL), single dose, abdominal subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 2mg
Description: 2mg (100μL), single dose, abdominal subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 5mg
Description: 5mg (250μL), single dose, abdominal subcutaneous injection
Study: NCT03616847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Hallux valgus/hallux rigidus surgery with the calf tourniquet remaining in situ until the wound is closed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tourniquet release
Description: Hallux valgus/hallux rigidus surgery with the calf tourniquet released five minutes before the wound is closed.
Study: NCT02158455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NT SVG grafts
Study: NCT03390296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study: NCT02158455

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NT SVG grafts
Study: NCT04312048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Description: one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion
Study: NCT01270724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).
Description: Two to four cycles of induction therapy with GemPOx followed by consolidation and ASCT.
Study: NCT02805959

Intervention type: DEVICE
Intervention: MTS2

Intervention type: DEVICE
Intervention: MTS2
Study: NCT04312048

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet of placebo vaginally 3 hours prior to copper IUD insertion
Study: NCT01864655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: oral drug given to experimental group
Study: NCT03390296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study: NCT01864655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: oral drug given to experimental group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: oral drug given to experimental group
Study: NCT01864655

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given to placebo group
Study: NCT01831648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Study: NCT03390296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study: NCT01119066

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: dose of 1375-1500 cGy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/kg/day x 2 or 10 mg/kg/day x 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/kg/day x 2 or 10 mg/kg/day x 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/kg/day x 2 or 10 mg/kg/day x 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70mg/m2/day x 2
Study: NCT01534494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: two doses of 0.3 mg/kg PO and 0.4 mg/kg PO, separated by 4 weeks in combination with 12 weeks of manualized outpatient psychosocial treatment including preparation, debriefing, and motivational enhancement therapy.
Study: NCT04135040

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Amino Acid
Description: 8 different lysine intakes (L-Amino Acid and food) will be tested for 8 hours each.
Study: NCT02680457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Insulin Degludec 10 IU SC every 24 hours for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Insulin Degludec 10 IU SC every 24 hours for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Insulin Glargine 10 IU SC every 24 hours for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Insulin Glargine 10 IU SC every 24 hours for 6 days
Study: NCT02724592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: self assembling peptide P11-4 (Curodont™ Repair)
Description: Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fluoride varnish (Duraphat®)
Description: Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fluoride varnish (Duraphat®)
Description: Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions
Study: NCT00140790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: valsartan 40 or 160 (80) mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: valsartan 40 or 160 (80) mg per day
Study: NCT03764787

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiation+PD-1 Ab
Description: combination of proton radiotherapy with PD-1 antibody
Study: NCT03459677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back2School
Description: Modular Trans-diagnostic Cognitive Behavioral Therapy treating school absenteeism in youths
Study: NCT01119066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70mg/m2/day x 2
Study: NCT03459677

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Aarhus municipality's treatment as usual for youths presenting school absenteeism
Study: NCT02317874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study: NCT00921154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Description: Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods with a 14 day wash-out period. Doses will be administered after an overnight fast.
Study: NCT02213744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Study: NCT01963780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCS Lung Preservation
Study: NCT01153308

Intervention type: OTHER
Intervention: Observational Study
Description: This is an Observational study
Study: NCT01119066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70mg/m2/day x 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25mg/m2/ day x 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 20mg/m2/ day x 5 (or, for children \<18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (CliniMACS) T-cell depleted PBSC Transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (CliniMACS) T-cell depleted PBSC Transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (CliniMACS) T-cell depleted PBSC Transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (CliniMACS) T-cell depleted PBSC Transplant
Study: NCT00407836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cell vaccination
Description: Approximately 10-20 million glutaraldehyde fixed CD4 responsive autologous T cells in 1-2 ml, per vaccine injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cell vaccination
Description: Approximately 10-20 million autologous CD4 reactive T cells per each vaccine injection
Study: NCT00821158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antioxidant
Description: Antioxidant iv bolus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet and iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory drug
Description: Anti-inflammatory tablet
Study: NCT03940989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HABIT-ILE
Description: Goal-directed, task-specific training for both the upper (UE) and lower extremity (LE) and postural control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HABIT-ILE
Description: Goal-directed, task-specific training for both the upper (UE) and lower extremity (LE) and postural control.
Study: NCT00839280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpanthenol foam spray, new formulation
Description: 2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexpanthenol foam spray, old formulation
Description: 2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
Study: NCT03794440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg IV d1， Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI305
Description: 15mg/kg IV d1， Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400mg PO BID
Study: NCT04277546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab Maintenance Dose
Description: Completers in the lead-in study D5272C00001 (Legacy #3151-201-008) will receive a maintenance dose of brazikumab administered subcutaneously every 4 weeks up to Week 52 (Group A). The SC dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab Induction Dose
Description: Participants in the lead-in study D5272C00001 (Legacy #3151-201-008) who have not responded to treatment and have met criteria for rescue treatment are considered inadequate/non-responders (Group B). In these eligible participants, IV induction dosing of brazikumab at Week 0, Week 4, and Week 8 will be administered, followed by brazikumab administered subcutaneously every 4 weeks thereafter (up to Week 52).
Study: NCT00841243

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrison (Nutricia)
Description: During 48 weeks of treatment, the patient will receive at T=0, 2, 4, 8, 12, 18, 24, 36, 48 weeks dietary advise combined with daily nutritional support in the form of a nutritional supplement drink at bedtime.
Study: NCT04787731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Local Anesthetic
Description: Long lasting local anesthetic administered to be compared to Lidocaine for quality of life outcomes in dental patients undergoing endodontic treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Local Anesthetic
Description: Long lasting local anesthetic administered to be compared to Lidocaine for quality of life outcomes in dental patients undergoing endodontic treatment
Study: NCT04071431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Result masking
Description: The quality control system randomly shows the RFQ result to the endoscopists and keep 50% of the RFQ results are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy.
Study: NCT02263872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 200mg perday

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Minocycline
Description: Minocycline 200mg perday
Study: NCT02691416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol postconditioning
Description: administrated Target Controlled Infusion(TCI) of propofol (Cp 1.2ug/ml) and decreased sevoflurane with a Bispectral index (BIS) value of 40-60 to maintain anesthesia after clamp removal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: 0.5%-2% sevoflurane with BIS 40-60

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: 0.5%-2% sevoflurane with BIS 40-60
Study: NCT02569463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks.
Study: NCT01736267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)
Description: Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
Study: NCT03627949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-intervention
Description: The intervention will address the basic elements of the HAPA model via the use of behaviour change techniques. In line with Abraham and Michie (2008), we use several behaviour change techniques like providing information about behavioural risk and benefit of behaviour change, prompting intention formation, prompting barrier identification, providing instructions how to perform a behaviour, prompting specific goal setting and review of behavioural goals, providing feedback on performance, prompting practice and providing follow-up prompts, prompting to plan social support and finally prompting relapse prevention, also based on strategies used by other effective computer tailoring programs. Students attended e-health intervention session once a week with about 20 minutes each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-intervention
Description: The intervention will address the basic elements of the HAPA model via the use of behaviour change techniques. In line with Abraham and Michie (2008), we use several behaviour change techniques like providing information about behavioural risk and benefit of behaviour change, prompting intention formation, prompting barrier identification, providing instructions how to perform a behaviour, prompting specific goal setting and review of behavioural goals, providing feedback on performance, prompting practice and providing follow-up prompts, prompting to plan social support and finally prompting relapse prevention, also based on strategies used by other effective computer tailoring programs. Students attended e-health intervention session once a week with about 20 minutes each time.
Study: NCT02578160

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inferior alveolar and lingual nerve block procedure
Description: inferior alveolar and lingual nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inferior alveolar and lingual nerve block procedure
Description: inferior alveolar and lingual nerve block
Study: NCT00361972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole
Description: 30 mg of lansoprazole twice daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks
Study: NCT01737762

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HP802-247
Description: HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x106 cells per mL every 14 days.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT01606904

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy -based weight loss program
Description: CBT-based program includes 20 group visits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy -based weight loss program
Description: CBT-based program includes 20 group visits